KMT2A and leukemia: Small molecule inhibitors of the menin–MLL interaction (generally referred to as menin inhibitors or MIs) have proven efficacious in reducing leukemic cell outgrowth and promoting differentiation in preclinical models of both MLLr and NPM1 mutant leukemias (reviewed in [171,172,173,174,175,176]).